  {"id":64005,"date":"2022-04-27T13:03:18","date_gmt":"2022-04-27T11:03:18","guid":{"rendered":"http:\/\/www.veeva.com\/eu\/?post_type=resources&#038;p=64005"},"modified":"2026-04-23T11:28:15","modified_gmt":"2026-04-23T09:28:15","slug":"leo-pharma-leverages-veeva-link-for-key-people-to-expand-engagement-with-scientific-experts","status":"publish","type":"resources","link":"https:\/\/www.veeva.com\/eu\/resources\/leo-pharma-leverages-veeva-link-for-key-people-to-expand-engagement-with-scientific-experts\/","title":{"rendered":"LEO Pharma Leverages ³Ô¹Ï±¬ÁÏ Link for Key People to Expand Engagement with Scientific Experts"},"content":{"rendered":"<p align=\"center\"><em>Global medical dermatology leader aims to more effectively engage with medical communities and advance new treatments that are expected to improve patients\u2019 quality of life <\/em><\/p>\n<p><strong>BARCELONA, Spain \u2014 27 April 2022  &#8211; <\/strong> <a href=\"\/eu\/\">³Ô¹Ï±¬ÁÏ Systems<\/a> (NYSE: VEEV) today announced that it has expanded its partnership with <a href=\"https:\/\/www.leo-pharma.com\/\" target=\"_blank\" rel=\"noopener noreferrer\">LEO Pharma<\/a>, a global leader in medical dermatology, to drive relevant discussions with the scientific community using <a href=\"\/eu\/products\/veeva-link\/\">³Ô¹Ï±¬ÁÏ Link for Key People<\/a>, a real time intelligence application from the ³Ô¹Ï±¬ÁÏ Link family of data products. Leveraging Link for Key People enables LEO Pharma\u2019s medical and sales teams to improve engagement efforts with medical experts in the dermatology community.<\/p>\n<p>\u201cAs we work to advance the standard of care in medical dermatology, it\u2019s crucial our teams have the latest insights from scientific, digital, and clinical leaders around the world,\u201d said Joshua Corriveau, senior director of global field medical excellence at LEO Pharma. \u201cAs we innovate in medical dermatology, we need accurate, timely data on the experts who are at the forefront of related research and development. Link for Key People will help us deepen relationships with known experts and identify new experts to foster scientific exchange that advances patient care.\u201d<\/p>\n<p>With plans to launch new treatments every two to three years, LEO Pharma\u2019s medical affairs team plays a vital role in engaging with scientific leaders globally. Through a nuanced understanding of each expert, they can enrich in-person and digital engagements in the evolving healthcare ecosystem. Link is seamlessly integrated with <a href=\"\/eu\/products\/crm-suite\/\">³Ô¹Ï±¬ÁÏ CRM<\/a>, delivering key insights across a range of sources, including activity from both global and local medical congresses, clinical trials, and digital engagement.<\/p>\n<p>\u201cConsidering LEO Pharma\u2019s rapid pace of clinical innovation, it\u2019s no surprise the company\u2019s medical and commercial teams are leading the way in precision engagement,\u201d said Kilian Weiss, general manager for ³Ô¹Ï±¬ÁÏ Link. \u201cBy leveraging our real-time customer intelligence to understand key leaders\u2019 scientific sentiment and professional networks, LEO Pharma\u2019s medical and commercial personnel can effectively engage key people to improve patient health and their quality of life.\u201d<\/p>\n<p>The addition of Link for Key People builds on LEO Pharma\u2019s use of <a href=\"\/eu\/products\/commercial-cloud\/\">³Ô¹Ï±¬ÁÏ Commercial Cloud<\/a>, including solutions for <a href=\"\/eu\/products\/crm-suite\/\">multichannel engagement<\/a> and <a href=\"\/eu\/products\/veeva-promomats\/\">commercial<\/a> and <a href=\"\/eu\/products\/vault-medical\/veeva-medcomms\/\">medical content management<\/a>, as well as its commitment as an early adopter of ³Ô¹Ï±¬ÁÏ\u2019s <a href=\"\/eu\/products\/veeva-clinical-platform\/\">digital trials platform<\/a>. To learn more about how Link for Key People helps biopharmas better understand the full impact of medical activities, identify new experts and healthcare providers to connect with, and drive more relevant, coordinated engagements, visit <a href=\"\/eu\/products\/veeva-link\/\">veeva.com\/eu\/³Ô¹Ï±¬ÁÏLink<\/a>.<\/p>\n<p>³Ô¹Ï±¬ÁÏ Link is part of <a href=\"\/eu\/products\/commercial-cloud\/\">³Ô¹Ï±¬ÁÏ Data Cloud<\/a>, a suite of data products built on a common architecture. For more information, see the ³Ô¹Ï±¬ÁÏ Summit keynotes on-demand at <a href=\"\/events\/commercial-summit\/keynotes\/\" target=\"_blank\" rel=\"noopener noreferrer\">veeva.com\/SummitKeynotes<\/a> and <a href=\"\/events\/commercial-summit\/keynotes\/?wvideo=y55j4ntni3\" target=\"_blank\" rel=\"noopener noreferrer\">veeva.com\/DataCloudKeynote<\/a>. Life sciences industry professionals can also <a href=\"\/events\/commercial-summit\/register\/\" target=\"_blank\" rel=\"noopener noreferrer\">register<\/a> for the ³Ô¹Ï±¬ÁÏ Commercial Summit for sales, medical, and marketing in Boston on May 5.<\/p>\n<p class=\"mb-10\"><strong>Additional Information<\/strong><br \/>\nFor more on ³Ô¹Ï±¬ÁÏ Link, visit: <a href=\"\/eu\/products\/veeva-link\/\">veeva.com\/eu\/³Ô¹Ï±¬ÁÏLink<\/a><br \/>\nConnect with ³Ô¹Ï±¬ÁÏ on LinkedIn: <a href=\"https:\/\/www.linkedin.com\/company\/veeva-systems\" target=\"_blank\" rel=\"noopener noreferrer\">linkedin.com\/company\/veeva-systems<\/a><br \/>\nFollow @veeva_eu on Twitter: <a href=\"https:\/\/www.twitter.com\/veeva_eu\" target=\"_blank\" rel=\"noopener noreferrer\">twitter.com\/veeva_eu<\/a><\/br>\n<\/p>\n<p class=\"mb-10\"><strong>About ³Ô¹Ï±¬ÁÏ Systems<\/strong><br \/>\n³Ô¹Ï±¬ÁÏ is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, ³Ô¹Ï±¬ÁÏ serves more than 1,000 customers, ranging from the world\u2019s largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, ³Ô¹Ï±¬ÁÏ is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit <a href=\"\/eu\/\">veeva.com\/eu<\/a>.<\/p>\n<p class=\"mb-10\"><strong>³Ô¹Ï±¬ÁÏ Forward-looking Statements<\/strong><br \/>\nThis release contains forward-looking statements regarding ³Ô¹Ï±¬ÁÏ\u2019s products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-K for the period ended January 31, 2022, which you can find <a href=\"https:\/\/www.sec.gov\/ix?doc=\/Archives\/edgar\/data\/1393052\/000139305222000017\/veev-20220131.htm\" target=\"_blank\" rel=\"noopener noreferrer\">here<\/a> (a summary of risks which may impact our business can be found on pages 13 and 14), and in our subsequent SEC filings, which you can access at <a href=\"https:\/\/www.sec.gov\/\" target=\"_blank\" rel=\"noopener noreferrer\">sec.gov<\/a>. <\/p>\n<p>###<\/p>\n<p><strong>Contact:<\/strong><\/p>\n<p>Deivis Mercado <br \/>\n³Ô¹Ï±¬ÁÏ Systems <br \/>\n925-226-8821 <br \/>\n<a href=\"mailto:deivis.mercado@veeva.com\">deivis.mercado@veeva.com<\/a><\/p>\n<p>Jeremy Whittaker<br \/>\n³Ô¹Ï±¬ÁÏ Systems<br \/>\n+49 6950955486<br \/>\n<a href=\"mailto:jeremy.whittaker@veeva.com\">jeremy.whittaker@veeva.com<\/a><\/p>\n<p>Henrik Heskjaer<br \/>\nLEO Pharma<br \/>\n+45-314-061-80<br \/>\n<a href=\"mailto:HDTDK@leo-harma.com\">HDTDK@leo-harma.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Global medical dermatology leader aims to more effectively engage with medical communities and advance new treatments that are expected to improve patients\u2019 quality of life.<\/p>\n","protected":false},"featured_media":64007,"parent":0,"template":"","class_list":["post-64005","resources","type-resources","status-publish","has-post-thumbnail","hentry","resource-area-20-commercial","resource-area-20-data","resource-area-20-medical","resource-product-20-real-time-customer-intelligence-link","resource-type-news-press-release","resource-type-press-release","region-de"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/resources\/64005"}],"collection":[{"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/resources"}],"about":[{"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/types\/resources"}],"version-history":[{"count":1,"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/resources\/64005\/revisions"}],"predecessor-version":[{"id":64010,"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/resources\/64005\/revisions\/64010"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/media\/64007"}],"wp:attachment":[{"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/media?parent=64005"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}